Sign in

    Matthew Guggenbiller

    Research Analyst at Bank of America

    Matthew Guggenbiller is an Equity Research Analyst at Bank of America, specializing in U.S. biopharmaceuticals with a particular focus on healthcare companies such as HUTCHMED China Limited and REGENXBIO. He regularly provides in-depth coverage and analysis for major public biopharma firms, actively participating in industry conferences and company earnings calls, though specific performance metrics or third-party rankings are not publicly documented. Guggenbiller's professional background centers on equity research, and he has been with Bank of America for several years, contributing to the institutional investment community. While publicly available sources do not specify securities licenses or FINRA registration, his analyst role at a major investment bank suggests adherence to industry regulatory standards.

    Matthew Guggenbiller's questions to Intellia Therapeutics (NTLA) leadership

    Matthew Guggenbiller's questions to Intellia Therapeutics (NTLA) leadership • Q2 2025

    Question

    Representing Alex Stranahan of Bank of America, Matthew Guggenbiller asked if the changes to enrollment targets and stabilizer percentage in the MAGNITUDE study have altered the company's thinking on the likelihood or timing of a potential interim readout.

    Answer

    President and CEO John Leonard confirmed that the adjustments increase the overall statistical power of the study for both the primary outcome and the stabilizer subgroup. He stated an expectation that these changes would "favorably affect the ability to find an effect" at the point of a future interim analysis.

    Ask Fintool Equity Research AI

    Matthew Guggenbiller's questions to AGIOS PHARMACEUTICALS (AGIO) leadership

    Matthew Guggenbiller's questions to AGIOS PHARMACEUTICALS (AGIO) leadership • Q2 2025

    Question

    Matthew Guggenbiller of Bank of America inquired about the educational strategy to drive Pyrokine uptake beyond the initial target patients in thalassemia and asked if development plans for the PKU asset, AG-181, have changed following a competitor's recent approval.

    Answer

    CCO Tsveta Milanova detailed plans to expand to less acute non-transfusion-dependent patients by educating on long-term complications. CMO Dr. Sarah Gheuens stated there are no changes to the PKU program, emphasizing AG-181's novel mechanism and the remaining unmet need in the patient population.

    Ask Fintool Equity Research AI